The RSK Inhibitor BIX02565 Limits Cardiac Ischemia/Reperfusion Injury.

Autor:	Shi X; Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., O'Neill MM; Department of CardioMetabolic Diseases Research, Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA., MacDonnell S; Department of CardioMetabolic Diseases Research, Boehringer-Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA., Brookes PS; Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Yan C; Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Berk BC; Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA bradford_berk@urmc.rochester.edu.
Jazyk:	angličtina
Zdroj:	Journal of cardiovascular pharmacology and therapeutics [J Cardiovasc Pharmacol Ther] 2016 Mar; Vol. 21 (2), pp. 177-86. Date of Electronic Publication: 2015 Jun 30.
DOI:	10.1177/1074248415591700
Abstrakt:	Aims: During ischemia/reperfusion (I/R), ribosomal S6 kinase (RSK) activates Na(+)/H(+) exchanger 1 (NHE1) by phosphorylating NHE1 at serine 703 (pS703-NHE1), which promotes cardiomyocyte death and injury. Pharmacologic inhibition of NHE1 effectively protects animal hearts from I/R. However, clinical trials using NHE1 inhibitors failed to show benefit in patients with acute myocardial infarction (MI). One possible explanation is those inhibitors block both agonist-stimulated activity (increasing I/R injury) and basal NHE1 activity (necessary for cell survival). We previously showed that dominant-negative RSK (DN-RSK) selectively blocked agonist-stimulated NHE1 activity. Therefore, we hypothesized that a novel RSK inhibitor (BIX02565) would blunt agonist-stimulated NHE1 and protect hearts from I/R. Methods and Results: Serum/angiotensin II-stimulated pS703-NHE1 was significantly decreased by BIX02565 in cultured cells. Intracellular pH recovery assay showed that BIX02565 selectively inhibited serum-stimulated NHE1 activity. Ischemia/reperfusion decreased left ventricular-developed pressure (LVDP; inhibited) to 8.7% of the basal level in non-transgenic littermate control (NLC) mouse hearts, which was significantly improved (44.6%) by BIX02565. Similar protection was observed in vehicle-treated, cardiac-specific DN-RSK-Tg mice (43%). No additional protective effect was seen in BIX02565-treated DN-RSK-Tg hearts. BIX02565 also improved LVDP in cardiac-specific wild-type (WT)-RSK-Tg mouse hearts (7.4%-40.9%, P < .01). Finally, Western Blotting results confirmed DN-RSK and BIX02565 significantly decreased I/R-induced pS703-NHE1. Conclusion: The RSK plays a crucial role in I/R-induced activation of NHE1 and cardiac injury. The RSK inhibition may provide an alternative target for patients with MI. (© The Author(s) 2015.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu